New weekly shot shows promise for kids with dwarfism
NCT ID NCT05598320
Summary
This trial tested whether a weekly injection could safely increase growth rate in children aged 2-11 with achondroplasia, a genetic condition that causes short stature. For one year, some children received the active injection while others received a placebo, followed by another year where all could receive the treatment. The main goal was to see if the treatment increased how fast the children grew each year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Saint Paul, Minnesota, 55102, United States
-
Ascendis Pharma Investigational Site
Columbia, Missouri, 65212, United States
-
Ascendis Pharma Investigational Site
Houston, Texas, 77030, United States
-
Ascendis Pharma Investigational Site
Madison, Wisconsin, 53705, United States
-
Ascendis Pharma Investigational Site
Parkville, 3052, Australia
-
Ascendis Pharma Investigational Site
Montreal, H3T 1CS, Canada
-
Ascendis Pharma Investigational Site
Copenhagen, 2100, Denmark
-
Ascendis Pharma Investigational Site
Dublin, D01 YC76, Ireland
-
Ascendis Pharma Investigational Site
Auckland, 1023, New Zealand
-
Ascendis Pharma Investigational Site
Vitoria-Gasteiz, 1008, Spain
Conditions
Explore the condition pages connected to this study.